Dec 15, 2020
Faster recovery reported with baricitinib/remdesivir therapy in ACTT-2
Among patients hospitalized for Covid-19, adding the anti-inflammatory drug baricitinib to remdesivir was associated with reduced time to recovery and faster improvement in clinical status in a second phase of the pivotal Adaptive Covid-19 Treatment Trial (ACTT).
The median recovery time among hospitalized patients receiving remdesivir and baricitinib was 7 days in the ACTT-2 trial, compared to 8 days in patients treated with remdesivir and placebo.
The difference was most pronounced among patients receiving high-flow oxygen or non-invasive ventilation at enrollment. Median recovery times among these patients was 10 days in the dual active therapy group and 18 days in the remdesivir and placebo group.
Tags »
In a randomized, controlled trial of more than 1,000 adults hospitalized with COVID-19 pneumonia, treatment with the anti-inflammatory drug baricitinib resulted in faster recovery and a greater likelihood of clinical improvement, when combined with the antiviral drug remdesivir.
The results of the international ACTT-2 (Adaptive COVID-19 Treatment Trial), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, were published Friday Dec. 11 in the
Baricitinib was originally developed by Eli Lilly and Company for rheumatoid arthritis and was FDA-approved for that indication in 2017. The drug, part of a class of drugs that inhibits JAK enzymes, received an emergency use authorization for COVID-19 treatment in November 2020, based upon the ACTT-2 results.
updated: Dec 14 2020, 09:09 ist
Adding an arthritis drug called baricitinib to Covid treatment regimens that include antiviral drug remdesivir might shave a day or more off recovery times, especially for those who are seriously sick, according to a study published Friday.
The findings of a government-sponsored clinical trial were made public more than three weeks after the Food and Drug Administration issued an emergency use authorization for the dual treatment. Earlier this month, some experts said they were uncomfortable deploying drugs without the opportunity to vet the underlying data supporting their performance. Last month, the World Health Organization also recommended against remdesivir as a treatment for Covid patients because evidence supporting its use was lacking.
This is incredible news : Nebraska hospitals, health departments prepare for COVID-19 vaccine arrivals
Local health departments are laying out their initial plans for a vaccination rollout, as hospital systems equip facilities with storage and distribution resources Share Updated: 6:38 PM CST Nov 18, 2020 This is incredible news : Nebraska hospitals, health departments prepare for COVID-19 vaccine arrivals
Local health departments are laying out their initial plans for a vaccination rollout, as hospital systems equip facilities with storage and distribution resources Share Updated: 6:38 PM CST Nov 18, 2020
Hide Transcript
Show Transcript AS OF TUESDAY, 978 PEOPLE WERE BEING TREATED FOR COVID-19 IN NEBRASKA HOSPITALS. THE DAY DOUGLAS COUNTY SHARES ITS VACCINATION PLAN. PFIZER ANNOUNCES ITS COVID-19 VACCINE IS NOW á95- PERCENT EFFECTIVE. COUNTY HEALTH LEADERS ALSO HIGHLIGHT PROMISING NEWS FROM MODERNA S VERSION BUT CAUTION THE FI
Covid Patient Study Shows Some Benefit From an Arthritis Drug nytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nytimes.com Daily Mail and Mail on Sunday newspapers.